Fourth Quarter 2022 and Subsequent Highlights: Announced topline results from Phase 1 study of RT-102. In December 2022, Rani announced topline results from Part 2 (repeat-dose portion) of the ...

Rani Therapeutics Holdings ... a lack of independent advancements or breakthroughs in their own product pipeline. The inclusion of forward-looking statements highlights potential risks and ...

Rani Therapeutics is a clinical stage biotech ... and highlight the important advancements that Rani has achieved in its pipeline over the past year. Then I will share how we are leveraging ...

Despite the revised timeline, Canaccord Genuity maintained a Buy rating on the company's shares, indicating its continued confidence in the potential of Rani Therapeutics' pipeline. These are the ...

Investors and stakeholders will be watching closely as Rani Therapeutics evaluates its strategic options moving forward. The company's actions will be guided by its commitment to advancing its ...

Rani Therapeutics shares are trading lower by 23% Tuesday afternoon. The company announced a $10 million direct offering of 3 million shares at $3 per share. Get stock picks, daily rankings ...

Rani Therapeutics Holdings ... and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti ...